Oncology Best Practice™ - Choosing Therapies for Patients with EGFR-Mutant Lung Cancers
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from AstraZeneca.
Interested in hosting an Oncology Best Practice™ EGFR program? Contact Sara Shaughnessy at Sshaughnessy@gotoper.com or call (609) 378-3701. Click here to download the Educational Request Form.
Oncology Best Practice™:
Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better Outcomes
December 2016-July 2017
In patients with advanced non–small cell lung cancers (NSCLCs) and mutations in the epidermal growth factor receptor (EGFR) gene, the development of EGFR tyrosine kinase inhibitors (TKIs) has undoubtedly improved therapeutic outcomes. Nevertheless, resistance to these agents occurs, which generally manifests as disease progression after initial therapeutic response. With the wide range of choices available through multiple lines of therapy, decisions regarding the best initial treatment, when to rebiopsy and/or retest for molecular markers (and the method by which to do so), selecting the best approach at the time of acquired drug resistance, and managing central nervous system (CNS) metastases are key in the care of these patients.
Accordingly, there is a need for educational activities in the community that illustrate how to navigate the nuances regarding the evaluation of acquired resistance, newer approaches to molecular testing, and choosing subsequent approaches to therapy. To meet these educational needs, this series of programs has recruited national experts who can synthesize recent data sets on newly available and late-stage investigational strategies to manage EGFR-mutated, advanced NSCLCs, and who can help place new evidence in its proper context for the practitioner challenged to manage patients with these tumors.
Key topics to be addressed include:
- Choosing the best initial therapy for patients with EGFR-mutated, advanced NSCLCs
- Best practices for molecular characterization of acquired resistance, including plasma- and tissue-based assays
- Optimal choice and timing of therapy in the second-line and beyond
- Current and emerging approaches to managing CNS metastases associated with EGFR-mutated NSCLCs
- Managing adverse events of therapy
This educational activity is directed toward medical oncologists who treat patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.
Upon completion of this activity, participants will be able to:
- Detail evidence that underlies the application of optimized front-line strategies to manage EGFR-mutated, advanced non–small cell lung cancers (NSCLCs)
- Describe methods to optimize EGFR subtyping and emerging technologies that can practically facilitate tumor testing, as well as overcome inherent challenges to optimized testing in community settings where advanced NSCLCs are managed
- Explain how to optimize the timing of clinical interventions in the relapsed, advanced NSCLC setting and the trial evidence that informs decision making to treat patients with EGFR-TKI resistance
- Address treatment-related toxicities and methods to optimize the management of CNS metastases in the care of patients with advanced NSCLCs.
MARK KRIS, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Calendar of Events